(Q61161077)

5

Guillermo Tortolero-Luna

0 references

Michele Follen

6

Michele Follen

0 references

Elizabeth R. Unger

8

Elizabeth R. Unger

0 references

Kevin L. Karem

2

Kevin Karem

0 references

author name string

Cynthia Bierl

1

0 references

Alysia C. Poon

3

0 references

David Swan

4

0 references

Louise Wideroff

7

0 references

William C. Reeves

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

9

0 references

language of work or name

English

0 references

publication date

December 2005

0 references

published in

Gynecologic Oncology

0 references

volume

99

0 references

issue

3

0 references

page(s)

S262-S268

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100

Immunity to oncogenic human papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100

Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100

A case-control study of human papillomavirus and cervical squamous intraepithelial lesions (SIL) in Harris County, Texas: differences among racial/ethnic groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100

Seroprevalence of human papillomavirus type 16 infection in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100

Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100

Immune responses to human papillomavirus in genital tract of women with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100

IgG antibodies against human papillomavirus type 16 E7 proteins in cervicovaginal washing fluid from patients with cervical neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100

Specific serologic response to genital human papillomavirus types in patients with vulvar precancerous and cancerous lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100

Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100

Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100

Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100

Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100

Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.100